SCIENTIFIC PROGRAM

All Sessions will be held at the Wohl Center Auditorium, Bar-Ilan University

All abstracts are published on the ISCR website (2012 Conference)

Tuesday, May 8, 2012

08:00-08:45 Registration, Coffee, Exhibition and Poster Mounting

08:45-09:00 OPENING REMARKS

Uri Nir - Chairperson, Organizing Committee
Benjamin Ehrenberg - VP for Research, Bar-Ilan University
Varda Rotter - President, ISCR

09:00-09:45 Session I: RNA AND CANCER

Chairpersons: **Gidi Rechavi,** Sheba Medical Center, Tel-Hashomer and Tel-Aviv University, Tel-Aviv, Israel
Doron Ginsberg, Bar-Ilan University, Ramat-Gan, Israel

09:00 THE SPLICING FACTOR hnRNP A2/B1 IS A DRIVING ONCOGENE IN BRAIN, BREAST AND LIVER CANCERS

Regina Golan-Gerstl[1], Asaf Shilo[1], Ilana Loinger[1], Ilan Stein[1], Eli Pikarsky[1], Reuven Reich[1], Ben Davidson[2], Jasmine Jacobs[3], Karen Cesarkas[3], Gideon Rechavi[3], Frank Rigo[4], Frank Bennett[4], **Rotem Karni**[1]
[1]*Hadassah Medical Center - The Hebrew University of Jerusalem, Jerusalem, Israel*
[2]*Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway*
[3]*Sheba Medical Center, Tel-Hashomer, Israel*
[4]*Isis Pharmaceuticals, Carlsbad, USA*

Session I (continued): RNA AND CANCER

09:20 FROM microRNA TO A NEW POSSIBLE THERAPEUTIC APPROACH IN EWING SARCOMA

Isaac Yaniv[1], Michal Hameiri-Grossman[1], Shifra Ash[2], Ian J. Cohen[2], Ronit Haklai[3], Galit Elad-Sfadia[3], Yoel Kloog[3], Elena Chepurko[4], Meora Feinmesser[5], Josephine Issakov[6], Osnat Sher[6], Drorit Luria[7], Isaac Meller[6], Yehuda Kollender[6], Abraham Weizman[1], Smadar Avigad[1]

[1]*Felsenstein MRC, Schneider Hospital and Tel-Aviv University, Petah-Tikva, Israel,* [2]*Schneider Children's Medical Center of Israel, Tel-Aviv University, Petah-Tikva, Israel,* [3]*Tel-Aviv University, Tel-Aviv, Israel,* [4]*Felsenstein Medical Research Center, Petah-Tikva, Israel,* [5]*Rabin Medical Center, Tel-Aviv University, Petah-Tikva, Israel,* [6]*Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel-Aviv, Israel,* [7]*Schneider Children's Medical Center of Israel, Petah-Tikva, Israel*

09:40-09:45 Discussion

09:45-10:30 Session II: INTERVENING WITH TUMOR GROWTH

Chairperson: **Ron N. Apte,** Ben-Gurion University of the Negev, Beer-Sheva, Israel

09:45 THE FUNCTION OF NCRS IN HEALTH AND DISEASE: EMPHASIS ON ISOFORMS

Angel Porgador, Michael Brusilovsky, Rami Yossef, Uzi Hadad, Michal Mendelson, Avishai Shemesh, Benyamin Rosental

Ben-Gurion University of the Negev, Beer-Sheva, Israel

10:05 RATIONAL DESIGN OF HEPARANASE INHIBITORS FOR CANCER THERAPY

Israel Vlodavsky

Technion-Israel Institute of Technology, Haifa, Israel

10:25-10:30 Discussion

10:30-11:15 ELIEZER FLESCHER MEMORIAL LECTURE

In Memoriam: **Yona Keisari,** Tel-Aviv University, Tel-Aviv, Israel
Introduction: **Moshe Oren**, Weizmann Institute of Science, Rehovot, Israel

10:30 *Invited lecture*
THE REGULATION AND ACTIVATION OF p53 FUNCTIONS BY A WIDE VARIETY OF STRESS SIGNALS PROTECTS US FROM CANCERS
Arnold Levine
Institute for Advanced Study, Princeton, USA

11:15-11:45 Coffee Break and Exhibition

11:45-13:30 Session III: NEW HORIZONS IN CANCER THERAPY-CROSSING THE PHASE I BARRIER

Chairpersons: **Tamar Peretz-Yablonski,** Hadassah Medical Center – The Hebrew University of Jerusalem, Jerusalem, Israel
Benjamin Sredni, Bar-Ilan University, Ramat-Gan, Israel

11:45 Introduction: **Varda Rotter,** Weizmann Institute of Science, Rehovot, Israel

Invited lecture
EVOLUTION OF THE CANCER GENOME
Mike Stratton
The Sanger Institute, Cambridgeshire, UK

12:30 CTLA-4 BLOCKADE: THE TRIUMPH AND DRAWBACKS OF THE FIRST WIDELY APPLIED IMMUNOTHERAPY FOR METASTATIC MELANOMA
Michal Lotem
Hadassah Medical Center - The Hebrew University of Jerusalem, Jerusalem, Israel

12:50 BIOLOGICAL AND IMMUNOLOGICAL ASPECTS OF TUMOR ABLATION BY INTRATUMORAL ALPHA RADIATION
Yona Keisari, Itzhak Kelson
Tel-Aviv University, Tel-Aviv, Israel

13:10 RAS CHAPERONS FOR CANCER THERAPY
Yoel Kloog
Tel-Aviv University, Tel-Aviv, Israel

13:30-14:00 CEREMONY IN HONOR OF ISAAC P. WITZ, FORMER ISCR PRESIDENT

BUSINESS SESSION

14:00-15:30 Light Lunch, Poster Session and Exhibition

14:30-15:30 POSTER SESSION - SELECTION OF PRIZE WINNING POSTERS

15:30-17:00 Session IV: OUTSTANDING POSTER PRESENTATIONS

Chairpersons: **Varda Rotter,** Weizmann Institute of Science, Rehovot, Israel
Uri Nir, Bar-Ilan University, Ramat-Gan, Israel

15:30 SPLIT IMMUNITY: IMMUNE INHIBITION OF RAT GLIOMAS BY SUBCUTANEOUS EXPOSURE TO UNMODIFIED LIVE TUMOR CELLS

Ilan Volovitz[1,2], Yotvat Marmor[2], Meir Azulay[2], Arthur Machlenkin[2], Ofir Goldberger[2], Felix Mor[2], Shimon Slavin[3], Zvi Ram[1], Irun R. Cohen[2], Lea Eisenbach[2]
[1] *Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel,* [2]*Weizmann Institute of Science, Rehovot, Israel,* [3]*Tel-Aviv Medical Complex, Tel-Aviv, Israel*

15:40 MESENCHYMAL STEM CELLS DELIVER SYNTHETIC microRNA MIMICS TO GLIOMA CELLS AND GLIOMA STEM CELLS AND INHIBIT CELL MIGRATION AND SELF-RENEWAL

Efrat Bucris[1], Ziv-Av Amotz[1], Lee Hae-Kyung[2], Susan Finniss[2], Simona Cazacu[2], Cunli Xiang[2], Kevin Bobbit[2], Sandra A. Rempel[2], Tom Mikkelsen[2], Shimon Slavin[3], Chaya Brodie[1,2]
[1]*Bar-Ilan University, Ramat-Gan, Israel,* [2]*Henry Ford Hospital, Detroit, USA,* [3]*Tel-Aviv Medical Complex, Tel-Aviv, Israel*

15:50 PROTEASOMES AND CANCER; FORMATION, ACTIVITY AND THERAPY

Yosef Shaul, Peter Tsvetkov, Julia Adler, Nadav Myers, Raz Eliav, Assaf Biran
Weizmann Institute of Science, Rehovot, Israel

Session IV (continued): OUTSTANDING POSTER PRESENTATIONS

16:00 TRANSCRIPTIONAL ACTIVITY OF ATF3 IN THE STROMAL COMPARTMENT OF TUMORS PROMOTES CANCER PROGRESSION

Shalom Madar[1], Yosef Buganim[1], Yoach Rais[1], Leslie Pomeraniec[1], Einav Harel[1], Hilla Solomon[1], Eyal Kalo[1], Ido Goldstein[1], Ran Brosh[1], Ora Haimov[1], Camila Avivi[2], Sylvie Polak-Charcon[2], Naomi Goldfinger[1], Iris Barshack[2], Varda Rotter[1]

[1]*Weizmann Institute of Science, Rehovot, Israel,* [2]*Sheba Medical Center, Tel-Hashomer, Israel*

16:10 MET REGULATION OF TUMOR GROWTH AND BLOOD FLOW

Sari Natan[1], Tammar Kushnir[2], Judith Horev[1], Ilan Tsarfaty[1], Galia Tsarfaty[2]

[1]*Tel-Aviv University, Tel-Aviv, Israel,* [2]*Sheba Medical Center, Tel-Hashomer, Israel*

16:20 EMT EPIGENETICS AND CANCER RISK MANAGEMENT

Izhak Haviv[1,3], Kornelia Polyak[2], Stephen Fox[3], Erik Thompson[3], Kristy Shield[3], Lorey Smith[3], Richard Tothill[3], Patrick Humbert[3], Alex Dobrovic[3], Saraswami Sukamar[4], Reo Maruyama[2], Sibgat Rauchaoudhuri[2], Geoff Macintyre[3], Adam Kowalczyk[3], Jasson Carroll[5]

[1]*Bar- Ilan University, Zfat, Israel,* [2]*Harvard, Boston, USA,* [3]*University of Melbourne, Melbourne, Australia,* [4]*Johns Hopkins, Baltimore, USA,* [5]*Cambridge, Cambridge, UK*

16:30 ACQUISITION OF CELL LINEAGE-SPECIFIC GENOMIC ABERRATIONS IN STEM CELLS IN-VITRO AND IN TUMORS IN-VIVO

Uri Ben-David, Yoav Mayshar, Nissim Benvenisty

The Hebrew University of Jerusalem, Jerusalem, Israel

16:40 ONCOGENE-INDUCED REPLICATION STRESS AND GENOME INSTABILITY ARE SIGNIFICANTLY ENHANCED BY FOLATE DEFICIENCY - A MODEL FOR THE ROLE OF ENVIRONMENTAL FACTORS IN GENOMIC INSTABILITY

Noa Lamm, Karin Maoz, Assaf C. Bester, Batsheva Kerem

The Hebrew University of Jerusalem, Jerusalem, Israel

16:50-17:00 Discussion

17:00-17:15 Closing Session:
BEST POSTER AWARD CEREMONY
CLOSING REMARS

POSTERS

14:30-15:30 POSTER SESSION

P-1 – P-90 Hall 1
P-91 – P-134 Hall 2

Board
No.

P-1 CD84 IS A SURVIVAL RECEPTOR FOR CLL CELLS
Inbal Binsky-Ehrenreich[1], Ayelet Marom[1], Mirko Sobota[1], Frida Lantner[1], Michal Haran[3], Yair Herishanu[2], Idit Shachar[1]
[1]*Weizmann Institute of Science, Rehovot, Israel,* [2] *Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel,* [3]*Kaplan Medical Center, Rehovot, Israel*

P-2 BLOOD GLUTAMATE SCAVENGERS PROLONG THE SURVIVAL OF RATS AND MICE WITH BRAIN-IMPLANTED GLIOMAS
Angela Ruban, Tamara Berkutzki, Itzik Cooper, Boaz Mohar, Vivian Teichberg
Weizmann Institute of Science, Rehovot, Israel

P-3 LUNG AND COLON CANCER-SPECIFIC REGULATION OF ALTERNATIVE SPLICING
Dror Hollander[1], Moritz Aschoff[2], Schraga Schwartz[3], Karl-Heinz Glatting[2], Roland Eils[2,4], Agnes Hotz-Wagenblatt[2], Rainer König[2,4], Gil Ast[1]
[1]*Tel-Aviv University, Tel-Aviv, Israel,* [2]*German Cancer Research Center (DKFZ), Heidelberg, Germany,*[3]*Harvard and MIT, Cambridge, USA,* [4]*University of Heidelberg, Heidelberg, Germany*

P-4 AS101 TREATMENT SENSITIZES ACUTE MYELOID LEUKEMIA CELLS (AML) TO CHEMOTHERAPY BY DISRUPTING THE INTERACTION BETWEEN VLA-4 INTEGRIN AND FIBRONECTIN:MECHANISMS OF ACTION AND CLINICAL APPLICATIONS
Adi Layani, Yona Kalechman, Benjamin Sredni
Bar-Ilan University, Ramat-Gan, Israel

Board
No.

P-5 EZH2 AND GATA3 PLAY OPPOSING ROLES IN CONTROLLING THE DIFFERENTIATION STATE OF BASAL-LIKE BREAST CANCER CELLS

Roy Granit[1], Tal Hadar[1], Yael Karamansha[1], Ithai Waldhorn[1], Irit Gat-Viks[2,4], Leah Liberman[1], Bella Maly[3], Tamar Peretz[3], Aviv Regev[4], Ittai Ben-Porath[1]
[1]*The Hebrew University of Jerusalem, Jerusalem, Israel*
[2]*Tel-Aviv University, Tel-Aviv, Israel*
[3] *Hadassah Medical Center - The Hebrew University of Jerusalem, Jerusalem, Israel*
[4]*Broad Institute of MIT and Harvard, Cambridge, USA*

P-6 FUNDAMENTAL CELL REGULATION BY ADAR1 ENZYME IS LOST IN METASTASIS BY microRNAs TO PROMOTE MALIGNANCY

Yael Wolff-Nemlich[1,2], Eyal Greenberg[1,2], Rona Ortenberg[1, 2], Michal J.Besser[1, 2], Iris Barshack[1], Jasmine Jacob-Hirsch[1], Elad Jacoby[1], Victor Prieto[3], Nitin Chakravarti[3], Lyn Duncan[4], David Kallenberg[5], Dorothy Bennett[5], Ninette Amariglio[1], Menashe Bar-Eli[3], Jacob Schachter[1], Gideon Rechavi[1,2], Gal Markel[1,2]
[1]*Sheba Medical Center, Tel-Hashomer, Israel,* [2] *Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel,* [3]*MD Anderson Cancer Center, Houston, USA,* [4]*Massachusetts General Hospital, Boston, USA*
[5]*St. George's, University of London, London, UK*

P-7 LOW LEVELS OF MIR-151-5p AND MIR-451 PREDICT RELAPSE IN PEDIATRIC B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA

Smadar Avigad[1,3], Iedan R.N. Verly[1,2], Gertjan J.L. Kaspers[2], Jacqueline Cloos[2], Anat Ohali[1,3], Michal Hameiri-Grossman[1,3], Keren Shichrur[1,3], Eva Fronkova[4], Jan Trka[4], Drorit Luria[3], Yona Kodman[3], Hadar Mirsky[1,3], Dafna Gaash[1,3], Marta Jeison[3], Galia Avrahami[3], Sara Elitzur[3], Gil Gilad[3], Batia Stark[3], Isaac Yaniv[1,3]
[1]*Felsenstein MRC, Petah-Tikva, Israel*
[2]*VU University Medical Center, Amsterdam, Netherlands*
[3]*Schneider Children's Medical Center of Israel, Petah-Tikva, Israel*
[4]*Charles University Prague, Prague, Czech Republic*

Board
No.

P-8 MIR-192 DIRECTLY REGULATES DICER1 IN NEUROBLASTOMA, LEADING TO A MORE AGGRESSIVE DISEASE

Galina Feinberg-Gorenshtein[1,2], Avital Guedj[1,2], Keren Shichrur[1,2], Marta Jeison[3], Drorit Luria[3], Shifra Ash[2,3], Meora Feinmesser[2,4], Liat Edry[5], Noam Shomron[5], Isaac Yaniv[1,2,3], **Smadar Avigad**[1,2,3]
[1]*Felsenstein MRC, Petah-Tikva, Israel,*
[2]*Tel-Aviv University, Tel-Aviv, Israel,* [3]*Schneider Children's Medical Center of Israel, Petah-Tikva, Israel,* [4]*Rabin Medical Center, Petah- Tikva, Israel,* [5]*Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel*

P-9 THE ROLE OF A-TO-I RNA EDITING ENZYME ADAR1 IN IMMUNE RESISTANCE OF MELANOMA CELLS

Gilli Galore Haskel[1,2], Yael Wolff-Nemlich[1,2], Mordechai Gutman[2], Jacob Schachter[2], Gal Markel[1,2]
[1]*Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel*
[2]*Sheba Medical Center, Tel-Hashomer, Israel*

P-10 ENGINEERING T CELLS TO IMPROVE HOMING CAPABILITIES TOWARDS HUMAN MELANOMA

Stav Kozlovski[1,2], Sivan Sapoznik[1], Michal J. Besser[1,2], Cyrille J. Cohen[3], Jacob Schachter[1], Gal Markel[1,2]
[1]*Sheba Medical Center, Tel-Hashomer, Israel*
[2]*Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel*
[3]*Bar-Ilan University, Ramat-Gan, Israel*

P-11 eIF4E TRANSLATION INITIATION FACTOR IS AN ATTRACTIVE THERAPEUTIC TARGET IN MULTIPLE MYELOMA

Oshrat Attar-Schneider[1,2], Liat Drucker[1,2], Victoria Zismanov[1,2], Shelly Tartakover Matalon[1,2], Michael Lishner[1,2]
[1]*Meir Medical Center, Kfar-Saba, Israel*
[2]*Tel-Aviv University, Tel-Aviv, Israel*

P-12 REDIRECTION OF T-CELLS FOR ADOPTIVE CELL TREATMENT OF CANCER IN A SPONTANEOUSLY PROGRESSING MAMMARY TUMOR MODEL

Anat Globerson, Tova Waks, Zelig Eshhar
Weizmann Institute of Science, Rehovot, Israel

Board
No.

P-13 CANCER ASSOCIATED FIBROBLASTS MEDIATE TUMOR-PROMOTING INFLAMMATION IN BREAST CANCER

Sarah Glanz[1], Charlotte Servais[1], Yael Raz[1], Camila Avivi[2], Iris Barshack[2], Neta Erez[1]
[1]*Tel-Aviv University, Tel-Aviv, Israel*
[2]*Sheba Medical Center, Tel-Hashomer, Israel*

P-14 THYROID HORMONES ANTAGONIZE AND TETRAC, A DEAMINATED T4 ANALOG, SENSITIZES BORTEZOMIB ACTION IN MULTIPLE MYELOMA CELLS

Keren Cohen[1,2], Martin Ellis[1], Shafik Khoury[1], Paul J. Davis[3], Aleck Hercbergs[4], Osnat Ashur-Fabian[1,2]
[1]*Meir Medical Center, Kfar Saba, Israel*
[2]*Tel-Aviv University, Tel-Aviv, Israel*
[3]*Ordway Research Institute, Albany, NY, USA*
[4]*The Cleveland Clinic Foundation, Cleveland, OH, USA*

P-15 HOST RESPONSE TO LOCAL RADIOTHERAPY MAY ENHANCE METASTATIC SPREAD IN MICE

Rotem Bril[1], Orit Kaidar-Person[2], Mark Shilkrut[2], Svetlana Gingis-Velitzki[1], Valeria Miller[1], Rahamim Ben-Yosef[2], Abraham Kuten[2], Yuval Shaked[1]
[1]*Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel,* [2]*Rambam Health Care Campus, Haifa, Israel*

P-16 VEGF-C SECRETED BY MACROPHAGES IN RESPONSE TO PACLITAXEL THERAPY MAY ACCOUNT FOR CHEMOTHERAPY-ENHANCED METASTASES IN MICE

Svetlana Gingis-Velitski[1], Dov Hershkovitz[3], Orit Kaidar-Person[2], Inna Naroditsky[2], Rotem Bril[1], Ella Fremder[1], Abraham Kuten[2], Yuval Shaked[1]
[1]*Rappaport Faculty of Medicine, Technion-Israel Institute of Technology Haifa, Israel*
[2]*Rambam Health Care Campus, Haifa, Israel*

Board
No.

P-17 MAMMARY FIBROBLASTS ARE ACTIVATED TO BECOME PRO-INFLAMMATORY BY BREAST TUMOR CELLS
Yoray Sharon, Lina Alon, Yael Raz, Neta Erez
Tel-Aviv University, Tel-Aviv, Israel

P-18 AMINO ACID STARVATION SENSITIZES CANCER CELLS TO PROTEASOME INHIBITION
Noam Cohen, Sarit Mizrachy-Schwartz, Shoshana Klein, Nataly Kravchenko-Balasha, Alexander Levitzki
The Hebrew University of Jerusalem, Jerusalem, Israel

P-19 TARGETING INSULIN RECEPTOR SUBSTRATES FOR DESTRUCTION AS A THERAPEUTIC MODALITY FOR CANCERS
Efrat Flashner[1], Hadas Reuveni[2], Lilach Steiner[1], Kirill Makedonski[1,2], Alexei Shir[1,2], Alexander Levitzki[1]
[1]*The Hebrew University of Jerusalem, Jerusalem, Israel*
[2]*NovoTyr Therapeutics, Tel-Hai, Israel*

P-20 E6 TOGETHER WITH E6AP UPREGULATE THE LEVELS OF β-CATENIN INDEPENDENT OF THE E6AP UBIQUITIN LIGASE ACTIVITY
Sophia Sominsky, **Yael Kuslansky**, Anna Jackman, Levana Sherman
Tel-Aviv University, Tel-Aviv, Israel

P-21 IMPAIRED ANGIOGENESIS MEDIATES DORMANCY OF HUMAN GLIOBLASTOMA-DERIVED CLONE: CROSSTALK BETWEEN POOR ANGIOGENIC POTENTIAL AND PROLONGED TUMOR DORMANCY
Shiran Ferber[1], Ehud Segal[1], Nava Almog[2], Ronit Satchi-Fainaro[1]
[1]*Tel-Aviv University, Tel-Aviv, Israel*
[2]*Tufts University School of Medicine, Boston, USA*

P-22 PACLITAXEL RESISTANCE CORRELATES WITH $\alpha_V\beta_3$ INTEGRIN EXPRESSION AND OVERCOMED WITH RGD-BEARING NANOCONJUGATE
Anat Eldar-Boock[1], Joaquin Sanchis[2], Ruth Lupu[3], María J. Vicent[2], Ronit Satchi-Fainaro[1]
[1]*Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel*
[2]*Centro de Investigación Príncipe Felipe, Valencia, Spain*
[3]*Mayo Clinic, Rochester, USA*

Board
No.

P-23 TUMOR-TARGETED DELIVERY OF SIRNA AS A DUAL ANTICANCER AND ANTI-ANGIOGENIC THERAPY

Paula Ofek[1], Wiebke Fischer[2], Marcelo Calderon[2], Fatemeh Sheikhi-Mehrabadi[2], Rainer Haag[2], Ronit Satchi-Fainaro[1]
[1]*Tel-Aviv University, Tel-Aviv, Israel*
[2]*Freie University, Berlin, Germany*

P-24 *BRAF* MUTATIONS, USE OF BEVACIZUMAB AND SURVIVAL OF COLORECTAL CANCER

Katerina Shulman[1,2], Ofra Barnett-Griness[1], Meira Frank[1], Abraham Kuten[2], Stephen B. Gruber[3], Flavio Lejbkowicz[1], Gad Rennert[1]
[1]*Carmel Medical Center and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel*
[2]*Rambam Health Care Campus, Haifa, Israel*
[3]*USC Norris Comprehensive Cancer Center, Los Angeles, USA*

P-25 AS101 PROTECTS AGAINST CHEMOTHERAPY-INDUCED FOLLICLE ACTIVATION AND INFERTILITY. A NOVEL SAFE APPROACH FOR FERTILITY PRESERVATION IN CANCER PATIENTS

Lital Kalich-Philosoph[1,2], Hadassa Roness[2], Alon Carmely[1,2], Hagai Ligumsky[2,3], Ido Wolf[2,3], Dror Meirow[2,3], Benjamin Sredni[1]
[1]*Bar-Ilan University, Ramat-Gan, Israel*
[2]*Sheba Medical Center, Tel-Hashomer, Israel*
[3]*Tel-Aviv University, Tel-Aviv, Israel*

P-26 MicroRNA125a-3p INHIBITS FYN-MEDIATED ONCOGENIC PATHWAY IN PROSTATE CANCER CELLS

Lihi Ninio-Many[1], Hadas Grossman[1], Irit Ben-Aharon[2], Salomon M. Stemmer[2], Noam Shomron[1], Ruth Shalgi[1]
[1]*Sackler Faculty of Medicine, Tel-Aviv University, Israel*
[2]*Rabin Medical Center, Tel-Aviv University, Petach-Tikva, Israel*

P-27 TUMOR CELL iNOS REGULATION BY miR-146a: TRANSLATIONAL INHIBITION AS MEANS TO ESCAPE MACROPHAGE-INDUCED DEATH

Miki Rahat, Miriam Walter, Nitza Lahat
Carmel Medical Center and Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

Board
No.

P-28 THE DIFFERENTIAL EFFECT OF ANTI-VEGF THERAPY IN MACROSCOPIC VERSUS MICROSCOPIC TUMORS MA DEPEND ON BMDC COLONIZATION OF TREATED TUMOR SITE

Dror Alishekevitz[1], Rotem Bril[1], Valeria Miller[1], Tali Voloshin[1], Svetlana Gingis-Velitski[1], Ella Fremder[1], Michal Munster[1], Stefan J. Scherer[2], Yuval Shaked[1]
[1]*Technion-Israel Institute of Technology, Haifa, Israel*
[2]*Hoffmann La Roche, Basel, Switzerland*

P-29 MALIGNANT OVARIAN ASCITES FLUID DERIVED CANCER CELL SUBPOPULATIONS PRESENT MARKERS CHARACTERISTIC OF CANCER STEM CELLS

Roni Shouval, Karl Skorecki, Maty Tzukerman
Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

P-30 MR AND HEMODYNAMIC RESPONSE IMAGING (HRI) FOR MONITORING THE EFFICACY OF A NOVEL ANTI-ANGIOGENESIS DRUG COMBINATION ON A NEUROBLASTOMA MOUSE MODEL

Chani Komar, Eitan Gross, Elia Dery, Nathalie Corchia, Keren Meir, Muli Ben-Sasson, Rinat Abramovitch
Hadassah Medical School - The Hebrew University of Jerusalem, Jerusalem, Israel

P-31 THE LATS2 TUMOR SUPPRESSOR AUGMENTS p53-MEDIATED APOPTOSIS

Yael Aylon[1], Norikazu Yabuta[2], Eleonora Lapi[3], Hiroshi Nojima[2], Xin Lu[3], Moshe Oren[1]
[1]*Weizmann Institute of Science, Rehovot, Israel*
[2]*Osaka University, Osaka, Japan*
[3]*University of Oxford, Oxford, UK*

P-32 ENHANCEMENT OF LYMPHOCYTE ANTI-TUMOR ACTIVITY USING CO STIMULATORY CHIMERIC RECEPTORS

Chen Ankri, Miri Fried, Cyrille J. Cohen
Bar-Ilan University, Ramat-Gan, Israel

Board
No.

P-33 MIRNA-MEDIATED TUMOR DORMANCY – THE ROLE OF MIR93 AND MIR200C IN THE ANGIOGENIC SWITCH
Galia Tiram[1], Ehud Segal[1], Gal Bachar[1], Roni Shreberk[1], Paula Ofek[1], Taturo Udagawa[2], Liat Edry[3], Noam Shomron[3], Ronit Satchi-Fainaro[1]
[1]*Tel-Aviv University, Tel-Aviv, Israel*
[2]*Children's Hospital Boston and Harvard Medical School, Boston, Massachusetts, USA,* [3]*Tel-Aviv University, Tel-Aviv, Israel*

P-34 MUTANT p53 PROLONGS NF-kappaB ACTIVATION AND PROMOTES COLITIS AND COLORECTAL TUMORIGENESIS
Tomer Cooks[1], Ioannis Pateras[2], Ohad Tarcic[1], Hilla Solomon[1], Eli Pikarsky[4], Giulermina Lozano[3], Varda Rotter[1], Vassilis Gorgoulis[2], Moshe Oren[1]
[1]*Weizmann Institute of Science, Rehovot, Israel,* [2]*University of Athens, Athens, Greece,* [3]*MD Anderson, Texas, USA,* [4]*Hadassah Medical School - The Hebrew University of Jerusalem, Jerusalem, Israel*

P-35 A SWITCH IN S6K1 ALTERNATIVE SPLICING MODULATES mTORC1 ACTIVITY
Vered Ben-Hur, Rotem Karni
Hadassah Medical School - The Hebrew University of Jerusalem, Jerusalem, Israel

P-36 FISHING FOR NEW BREAST AND OVARIAN CANCER GENES
Carmit Strauss, Michal Goldberg
The Hebrew University of Jerusalem, Jerusalem, Israel

P-37 RBM38 IS A DIRECT TRANSCRIPTIONAL TARGET OF E2F1 THAT LIMITS E2F-INDUCED PROLIFERATION
Orit Feldstein, Doron Ginsberg
Bar-Ilan University, Ramat-Gan, Israel

P-38 THE LONG NON-CODING RNA ANRIL IS A DIRECT TRANSCRIPTIONAL TARGET OF E2F1 THAT MEDIATES E2F1-INDUCED PROLIFERATION
Dana Bashari, Adi Jerbi, Orit Feldstein, Doron Ginsberg
Bar-Ilan University, Ramat-Gan, Israel

Board
No.

P-39 TARGETING OF TUMORS BY T-LYMPHOCYTES ENGINEERED TO EXPRESS NK RECEPTORS

Shlomo Yaacobi[1], Yair Tal[1], Miryam Horovitz-Fried[1], Angel Porgador[2], Cyrille J. Cohen[1]
[1]*Bar-Ilan University, Ramat-Gan, Israel*
[2]*Ben-Gurion University of the Negev, Beer-Sheva, Israel*

P-40 INDUCTION OF ANTI-TUMOR IMMUNITY AGAINST MOUSE COLON CARCINOMA TUMORS FOLLOWING TUMOR ABLATION BY INTRATUMORAL ^{224}Ra-LOADED WIRES

Hila Confino[1], Ilan Hochman[1], Margalit Efrati[1], Michael Schmidt[2], Gideon Halperin[1], Itzhak Kelson[2], Yona Keisari[1]
[1]*Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel*
[2]*Sackler Faculty of Exact Sciences, Tel-Aviv University, Tel-Aviv, Israel*

P-41 A PHENANTHRENE DERIVED PARP INHIBITOR EXCLUSIVELY ERADICATES HUMAN CANCER CELLS BY 'MITOTIC CATASTROPHE' CELL DEATH

Malka Cohen-Armon[1], Asher Castiel[2], Leonid Visochek[1], Shai Izraeli[1,2], Françoise Dantzer[3]
[1]*Tel-Aviv University, Tel-Aviv, Israel,* [2]*Sheba Medical Center, Tel-Hashomer, Israel,* [3]*Ecole Superieure de Biotechnologie Strasbourg, Strasbourg, France*

P-42 FOLATED DRUG DELIVERY SYSTEMS OF DOXORUBICIN FOR THE TREATMENT OF CANCER

Anna Scomparin[1], Anat Eldar-Boock[1], Shiran Ferber[1], Galia Tiram[1], Hilary Shmeeda[2], Alberto Gabizon[2], Stefano Salmaso[3], Paolo Caliceti[3], Ronit Satchi-Fainaro[1]
[1]*Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel*
[2]*Shaare Zedek Medical Center and Hadassah Medical School - The Hebrew University of Jerusalem, Jerusalem, Israel,* [3]*University of Padova, Padova, Italy*

P-43 p53, A NOVEL REGULATOR OF LIPID METABOLISM PATHWAYS

Ido Goldstein, Osnat Ezra, Noa Rivlin, Alina Molchadsky, Shalom Madar, Naomi Goldfinger, Varda Rotter
Weizmann Institute of Science, Rehovot, Israel

Board
No.

P-44 METABOLIC PHENOTYPIC ANALYSIS UNCOVERS REDUCED PROLIFERATION IN LATE STAGE BREAST CANCER

Livnat Jerby[1], Lior Wolf[1], Carsten Denkert[2], Gideon Y. Stein[1,3], Mika Hilvo[4], Matej Oresic[4], Tamar Geiger[1], Eytan Ruppin[1]
[1]*Tel-Aviv University, Tel-Aviv, Israel,* [2]*Charité Hospital, Berlin, Germany,* [3]*Beilinson Hospital, Rabin Medical Center Israel, Petah-Tikva, Israel,* [4]*Technical Research Centre of Finland, Espoo, Finland*

P-45 PSYCHOLOGICAL RISK FACTORS FOR COLORECTAL CANCER?

Shulamith Kreitler[1], Michal M. Kreitler[2], Asaf Len[3], Frida Barak[4]
[1]*Tel-Aviv University and Sheba Medical Center, Tel-Aviv, Israel*
[2]*Tel-Aviv University, Tel-Aviv, Israel,* [3]*Wolfson Hospital, Holon, Israel*
[4]*Barzilai Medical Center, Ashkelon, Israel*

P-46 FUNCTIONAL GENOMICS UNRAVEL THE ROLE OF ERG IN THE DEVELOPMENT OF ACUTE MYELOID LEUKEMIA AND IDENTIFIES THERAPEUTIC TARGETS

Liat Goldberg[1,3], Yehudit Birger[1], Marloes Tijssen[2], Rebecca Hanna[2], Berthold Gottgens[2], Jasmine Jaccob-Hirsch[1], Anat Taragan[3], Yoel Kloog[3], Shai Izraeli[1,3]
[1]*Sheba Medical Center, Tel-Hashomer, Israel*
[2]*University of Cambridge, Cambridge Institute for Medical Research, Cambridge, UK*
[3]*Tel-Aviv University, Tel-Aviv, Israel*

P-47 SILENCING OF A LARGE micro-RNA CLUSTER ON HUMAN CHROMOSOME 14q32 IN MELANOMA: BIOLOGICAL EFFECTS OF mir-376a and mir-376c ON INSULIN GROWTH FACTOR 1 RECEPTOR

Liron Zehavi[1,2], Raya Leibowitz-Amit[2], Dror Avni[2], Yehezkel Sidi[1,2]
[1]*Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel*
[2]*Sheba Medical Center, Tel-Hashomer, Israel*

Board
No.

P-48 A CROSS-TALK BETWEEN p53 AND Ras IN THE MALIGNANT PROCESS
Hilla Solomon[1], Yosef Buganim[1], Leslie Pomeraniec[1], Tsevi Beatus, Yael Assia, Ira Kogan-Sakin, Shalom Madar, Ido Goldstein, Ran Brosh, Eyal Kalo, Naomi Goldfinger, Varda Rotter
Weizmann Institute of Science, Rehovot, Israel

P-49 CARBOXYPEPTIDASE E (CPE) - A NEGATIVE REGULATOR OF THE CANONICAL Wnt SIGNALING PATHWAY
Nir Skalka, Michal Caspi, Rina Rosin-Arbesfeld
Tel-Aviv University, Tel-Aviv, Israel

P-50 COMPARING TÊTE-À-TÊTE LINEAR AND SPHERICAL POLYMERIC ARCHITECTURES FOR TARGETED DELIVERY OF DOXORUBICIN
Dina Polyak[1], Claudia Ryppa[2], Felix Kratz[2], Boris Polyak[3], Ronit Satchi-Fainaro[1]
[1]*Tel-Aviv University, Tel-Aviv, Israel,* [2]*Tumor Biology Center, Freiburg, Germany,* [3]*Drexel University College of Medicine, Philadelphia, USA*

P-51 TUMOR ASSOCIATED NEUTROPHIL (TAN) DEVELOP PRO-TUMORIGENIC PROPERTIES DURING TUMOR PROGRESSION
Inbal Mishalian, Bayuch Rachel, Zolotriob Lida, Levy Liran, Fridlender Zvi
Hadassah Medical Center - The Hebrew University of Jerusalem, Jerusalem, Israel

P-52 THE INFLUENCE OF P53 MUTATIONS ON ITS PRESENTATION BY THE MHC SYSTEM
Katrina Shamalov, Shlomo Levy, Miryam Horovitz-Fried, Cyrille J. Cohen
Bar-Ilan University, Ramat Gan, Israel

Board
No.

P-53 FIBROBLAST GROWTH FACTOR RECEPTORS IN MELANOMA: POTENTIAL TARGETS FOR INHIBITION OF TUMOR GROWTH AND METASTASIS?

Michael Grusch[1,2], Sivan Izraely[2], Karin Schelch[1], Shlomit Ben-Menahem[2], Maayan Tahor[2], Anat Klein[2], Petra Heffeter[1], Christine Pirker[1], Orit Sagi-Assif[2], Walter Berger[1], Isaac P. Witz[2]
[1]*Medical University of Vienna, Vienna, Austria,* [2]*Tel-Aviv University, Tel-Aviv, Israel*

P-54 THE CYTOKINE MIDKINE AND ITS RECEPTOR RPTPz REGULATE B CELL SURVIVAL IN A PATHWAY INDUCED BY CD74

Sivan Cohen[1], Or-yam Shoshana[1], Einat Zelman-Toister[1], Nitsan Maharshak[1], Inbal Binsky-Ehrenreich[1], Maya Gordin[1], Lev Shvidel[2], Michal Haran[2], Lin Leng[3], Richard Bucala[3], Sheila Harroch[4], Idit Shachar[1]
[1]*Weizmann Institute of Science, Rehovot, Israel,* [2]*Kaplan Medical Center, Rehovot, Israel,* [3]*University School of Medicine, New Haven, USA,* [4]*Institut Pasteur, Paris, France*

P-55 γδT CELLS FOR ADOPTIVE IMMUNOTHERAPY OF GLIOBLASTOMA MULTIFORME

Victoria Marcu, Naama Peshes-Yaloz, Zvi Cohen, Ilan Bank
Sheba Medical Center, Tel-Hashomer, Israel

P-56 DOWNREGULATION OF MIR-31, MIR-155, AND MIR-564 IN CHRONIC MYELOID LEUKEMIA CELLS

Oshrat Hershkovitz-Rokah[1], Galit Granot[1], Adelina Ovcharenko[1], Shira Modai[2], Metsada Pasmanik-Chor[2], Amos Toren[3], Noam Shomron[2], Ofer Shpilberg[1]
[1]*Beilinson Hospital, Sackler School of Medicine, Tel-Aviv University, Petah-Tikva, Israel*
[2]*Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel*
[3]*Safra Children's Hospital, Tel-Hashomer, Israel*

Board
No.

P-57 CANCER and DEVELOPMENT: PERTURBATION OF FETAL HEMATOPOIESIS IN A MOUSE MODEL OF DOWN SYNDROME TRANSIENT MYELOPROLIFERATIVE DISORDER
Yehudit Birger[1], Liat Goldberg[1], Inna Muler[1], Jasmin Jacob-Hirsch[1], Shai Izraeli[2]
[1]*Sheba Medical Center, Tel-Hashomer, Israel*
[2]*Sheba Medical Center and Tel-Aviv University, Tel-Hashomer, Israel*

P-58 CURE OF PRIMARY TUMORS BY ELECTRIC BASED-ABLATION CAN STIMULATE ANTI TUMOR IMMUNITY
Ilan Hochman, Hila Confino, Margalit Efrati, Rafi Korenstein, Yona Keisari
Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

P-59 CHARACTERIZATION OF KLOTHO FUNCTION-STRUCTURE RELATIONSHIP
Keren Merenbakh[1,2], Hagai Ligumsky[1,2], Shiri Shahmoon[1,2], Tami Rubinek[1], Ido Wolf[1,2]
[1]*Sheba Medical Center, Tel-Hashomer, Israel*
[2]*Tel-Aviv University, Tel-Aviv, Israel*

P-60 DIFFERENTIAL EFFECTS OF KLOTHO ON OXIDATIVE STRESS IN NORMAL AND BREAST CANCER CELLS
Irina Lojkin[1,2], Tami Rubinek[1], Ido Wolf[1,2]
[1]*Sheba Medical Center, Tel-Hashomer, Israel,* [2]*Tel-Aviv University, Tel- Aviv, Israel*

P-61 AN HCC GENOMIC AMPLIFICATION REGULATES THE TUMOR MICROENVIRONMENT AND MARKS TUMORS SENSITIVE FOR VEGF-A INHIBITION
Elad Horwitz[1], Ilan Stein[1,3], Julia Nemeth[2], Avivit Shoham[1], Orit Pappo[3], Naama Kanarek[1], Farid Zreik[1,3], Rinnat Porat[1,3], Hendrik Reuter[2], Jochen Hess[2], Kai Breuhahn[2], Peter Angel[2], Yinon Ben-Neriah[1], Eli Pikarsky[1,3]
[1]*The Hebrew University of Jerusalem, Jerusalem, Israel*
[2]*German Cancer Research Center (DKFZ), Heidelberg, Germany*
[3]*Hadassah Medical Center - The Hebrew University of Jerusalem, Jerusalem, Israel*

Board
No.

P-62 RTVP-1 IS ASSOCIATED WITH THE MESENCHYMAL DIFFERENTIATION OF GLIOMA AND GLIOMA STEM CELLS (GSCs) AND PROMOTES THEIR SELF-RENEWAL

Nissim Giladi[1], Amotz Ziv-Av[1], Hae Kyung Lee[2], Susan Finniss[2], Simona Cazacu[2], Cunli Xiang[2], Laila Poisson[2], Tom Mikkelsen[2], Chaya Brodie[1,2]
[1]*Bar-Ilan University, Ramat-Gan, Israel,* [2]*Henry Ford Hospital, Detroit, USA*

P-63 REGULATION OF GLIOMA CELL MIGRATION AND INVASION BY RTVP-1

Nissim Giladi[1], Amotz Ziv-Av[1], Hae-Kyung Lee[2], Simona Cazacu[2], Susan Finniss[2], Cunli Xiang[2], Chaya Brodie[1,2]
[1]*Bar-Ilan University, Ramat-Gan, Israel,* [2]*Henry Ford Hospital, Detroit, USA*

P-64 KLOTHO-INDUCED DISSOCIATION BETWEEN ACTIVATION AND NUCLEAR LOCALIZATION OF EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK) 1/2: A NOVEL GROWTH INHIBITORY MECHANISM IN BREAST CANCER

Shiri Shahmoon[1,2], Tami Rubinek[1], Rony Seger[3], Ido Wolf[1,2]
[1]*Sheba Medical Center, Tel-Hashomer, Israel,* [2]*Sackler Faculty of Medicine, Tel-Aviv, Israel,* [3]*Weizmann Institute of Science, Rehovot, Israel*

P-65 KLOTHO, A NOVEL REGULATOR OF SOMATOTROPE PROLIFERATION AND HORMONE SECRETION

Shiri Shahmoon[1,3], Hadara Rubinfeld[2], Ido Wolf[1,3], Tami Rubinek[1]
[1]*Sheba Medical Center, Tel-Hashomer, Israel,* [2]*Rabin Medical Center, Petah-Tikva,* [3]*Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel*

P-66 NEW VIEWS ON microRNAs INVOLVEMENT IN MELANOMA

Eyal Greenberg[1,2], Eran Eyal[1], Liat Hershkovitz[1], Yael Nemlich[1], Steven Hajdu[1], Orit Itzhaki[1], Liat Edry[2], Oz Solomon[1,3], Ninette Amariglio[1], Michal J. Besser[1], Yona Keisari[2], Gideon Rechavi[3,7], Noam Shomron[4], Jacob Schachter[1], Gal Markel[1,2]
[1]*Sheba Medical Center, Tel-Hashomer, Israel,* [2]*Tel-Aviv University, Tel-Aviv, Israel,* [3]*Bar-Ilan University, Ramat-Gan, Israel*

Board
No.

P-67 TOWARDS RESTORING FOLDING AND FUNCTION OF MUTANT P53 *IN VIVO*
Gal Herzog, Liel Aillenberg, Merav Shmueli, Michaela Yanku, Meital Asher, Michal Levy, Ehud Gazit, Daniel Segal
Tel-Aviv University, Tel-Aviv, Israel

P-68 ADAR1 and ADAR3 EXPRESSION IS DECREASED IN GLIOBLASTOMA AND THEY REGULATE GLIOMA CELL MIGRATION AND RESPONSE TO RADIO- AND CHEMO-THERAPY
Anna Dubnik[1], Susan Finniss[2], Cunli Xiang[2], Simona Cazacu[2], Ninette Amariglio[3], Gideon Rechavi[3], Chaya Brodie[1]
[1]*Bar-Ilan University, Ramat-Gan,* [2]*Henry Ford Hospital, Detroit, USA*
[3]*Sheba Medical Center, Tel-Hashomer, Israel*

P-69 4-1BB TRANSDUCED HUMAN T CELLS DEMONSTRATE AN IMPROVED ANTI-TUMOR ACTIVITY
Inbal Daniel-Meshulam, Cyrille J. Cohen
Bar-Ilan University, Ramat-Gan, Israel

P-70 GRANULE EXOCYTOSIS MEDIATES IMMUNE SURVEILLANCE OF SENESCENT CELLS
Adi Sagiv[1], Anat Biran[1], Scott W. Lowe[2], Valery Krizhanovsky[1]
[1]*Weizmann Institute of Science, Rehovot, Israel*
[2]*Memorial Sloan-Kettering Cancer Center, New York, USA*

P-71 BIOMARKER ROBUSTNESS REVEALS THE PDGF NETWORK AS DRIVING DISEASE OUTCOME IN OVARIAN CANCER PATIENTS IN MULTIPLE STUDIES
Rotem Ben-Hamo, Sol Efroni
Bar-Ilan University, Ramat-Gan, Israel

P-72 GENE EXPRESSION AND NETWORK-BASED ANALYSIS REVEALS A NOVEL ROLE FOR hsa-miR-9 AND DRUG CONTROL OVER THE p38 NETWORK IN GLIOBLASTOMA MULTIFORME PROGRESSION
Rotem Ben-Hamo, Sol Efroni
Bar-Ilan University, Ramat-Gan, Israel

Board
No.

P-73 THE EFFECT OF FORCHLORFENURON ON HIF-1a PROTEIN IN CANCER CELLS
Dikla Vardi-Oknin, Maya Golan, Nicola Mabjeesh
Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv, Israel

P-74 GATA3 REGULATES CELLULAR PHENOTYPES IN BREAST CANCER
Ilana Brutman, Helit Cohen, Sol Efroni
Bar-Ilan University, Ramat-Gan, Israel

P-75 STIL, A PROTEIN OVEREXPRESSED IN MULTIPLE CANCERS, IS REQUIRED FOR CENTRIOLE DUPLICATION AND PRIMARY CILIA ORGANNELE FORMATION IN MAMMALIAN CELLS
Ahuvit David[1,2], Julia Vulprecht[3], Asher Castiel[1,2], Alwin Krämer[3], Shai Izraeli[1,2]
[1]*Sheba Medical Center, Tel-Hashomer, Israel,* [2]*Tel-Aviv University, Tel-Aviv, Israel,* [3]*University of Heidelberg, Heidelberg, Germany*

P-76 FROM SPERMATOGENESIS TO CANCER CELLS: THE MITOCHONDRIAL FER T/FER LINK
Ariela Segal, Etai Yaffe, Elad Hikri, Adar Makovski, Sally Shpungin, Uri Nir
Bar-Ilan University, Ramat-Gan, Israel

P-77 HIF-1a and β-TrCP INTERACTIONS IN CANCER CELLS
Maya Cohen, Maya Golan, Nicola Mabjeesh
Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel-Aviv, Israel

P-78 ENHANCING THE ANTI-TUMOR ACTIVITY OF T CELLS BY IMPROVING THE EXPRESSION OF THE TCR CHAINS USING DIFFERENT LEADER SEQUENCES
Viki Raz Djanashvili, Miryam Horovitz-Fried, Cyrille J. Cohen
Bar-Ilan University, Ramat-Gan, Israel

Board
No.

P-79 SECOND GENERATION TYROSINE KINASE INHIBITORS REDUCE TELOMERASE ACTIVITY IN K562 CELLS
Saar Shapira, Rahav Mor-Tzuntz, Galit Granot, Pia Raanani, Orit Uziel, Meir Lahav, Ofer Shpilberg
Belinson Hospital, Tel-Aviv University, Petach-Tikva, Israel

P-80 SPLENCTOMY INHIBITS TUMOR DEVELOPMENT AND METASTASES IN MURINE LUNG CANCER MODELS
Liran Levy, Inbal Mishalian, Lida Zolotarob, Rachel Bayuh, Zvi Fridlender
Hadassah Medical Center - The Hebrew University of Jerusalem, Jerusalem, Israel

P-81 A POSSIBLE ROLE FOR PHOX2B IN THE SWITCH FROM MICRO TO MACRO METASTASIS IN NEUROBLASTOMA
Maayan Tahor, Shelly Maman, Tsipi Meshel, Ilana Yron, Isaac P. Witz, Orit Sagi-Assif
Tel-Aviv University, Tel-Aviv, Israel

P-82 CLASSIFYING DISEASE EXPRESSION PROFILES USING NETWORKS
Ofer Lavi[1], **David Amar**[1], Gideon Dror[2], Ron Shamir[1]
[1]*Tel Aviv University, Tel-Aviv, Israel,* [2]*Tel-Aviv College, Tel-Aviv, Israel*

P-83 IDENTIFYING SPLICING TARGETS OF THE SPLICING FACTOR HNRNP A2/B1 IN BREAST CANCER USING NEXT GENERATION RNA SEQUENCING
Ilana Loinger-Lebenthal[1], Regina Golan-Gerstl[1], Jasmine Jacob- Hirsch[2], Karen Cesarkas[2], Gideon Rechavi[2], Rotem Karni[1]
[1]*Hadassah Medical School - The Hebrew University of Jerusalem, Jerusalem, Israel*
[2]*Sheba Medical Center, Tel-Hashomer, Israel*

Board
No.

P-84 ENHANCED ADHESION AND MIGRATION AND INDUCTION OF Pyk2 comPlex FOMATION IN NB4 CELLS FOLLOWING ATRA TREATMENT

Adelina Ovcharenko[1], Galit Granot[1], Ofer Shpilberg[2], Pia Raanani[2]
[1]*Felsenstein MRC, Sackler School of Medicine, Tel-Aviv University, Petach-Tikva, Israel,* [2]*Beilinson Hospital, Sackler School of Medicine, Tel-Aviv University, Petach-Tikva, Israel*

P-85 INTRATUMORAL ALPHA RADIATION EFFECTIVELY ABLATED TRANSPLANTED MURINE BREAST TUMORS AND RELEASED ANTIGENS WHICH TRIGGERED PROTECTIVE ANTI-TUMOR IMMUNITY

Margalit Efrati[1], Hila Confino, Ilan Hochman, Michael Schmidt, Itzhak Kelson, Yona Keisari
Tel-Aviv University, Tel-Aviv, Israel

P-86 RNF20 AS A POSSIBLE MOLECULAR LINK BETWEEN INFLAMMATION AND CANCER

Ohad Tarcic, Tomer Cooks, Moshe Oren
Weizmann Institute of Science, Rehovot, Israel

P-87 THE AFFECT OF TUMOR-SUPPRESSOR LOSS ON REPLICATION DYNAMICS IN EARLY STAGES OF TUMORIGENESIS

Maayan Roniger, Assaf C. Bester, Batsheva Kerem
The Hebrew University of Jerusalem, Jerusalem, Israel

P-88 EXPLOITING BRIGHT FIELD MICROSCOPY TO QUANTIFY COLLECTIVE CELLS MIGRATION

Assaf Zaritsky, Sari Natan, Eshel Ben-Jacob, Ilan Tsarfaty
Tel-Aviv University, Tel-Aviv, Israel

P-89 EXPOSURE TO LIGHT AT NIGHT AND ITS ASSOCIATION WITH BREAST CANCER - CAN WE THINK ON WAYS OF PREVENTION?

Atalya Keshet - Sitton, Abraham Haim
Haifa University, Haifa, Israel

Board
No.

P-90 A SENESCENCE-INFLAMMATORY SWITCH FROM CANCER-INHIBITORY TO CANCER-PROMOTING MECHANISM

Ela Elyada[1], Ariel Pribluda[1], Zoltan Wiener[2], Robert Goldstein[1], Ido B[1], Yael Morgenstern[1], Guy Brachya[1], Sharon Biton[1], Irit Alkalay[1], Moshe Oren[3], Kari Alitalo[2], Eli Pikarsky[1,4], Yinon Ben-Neriah[1]
[1]The *Hebrew University of Jerusalem, Jerusalem, Israel*
[2]*University of Helsinki, Helsinki, Finland,* [3]*Weizmann Institute of Science, Rehovot, Israel,* [4] *Hadassah Medical School - The Hebrew University of Jerusalem, Jerusalem, Israel*

Board
No.

P-91 CAN DNA REPLICATION DYNAMICS AND GENOMIC STABILITY BE AFFECTED BY INTRODUCING FRA16C-DERIVED AT-RICH SEQUENCE INTO ECTOPIC LOCI?

Michal Irony-Tur Sinai, Batsheva Kerem
The Hebrew University of Jerusalem, Jerusalem, Israel

P-92 SERUM CEACAM1 AS A BIOMARKER FOR MONITORING OF MELANOMA PATIENTS

Rona Ortenberg[1,2], Sivan Sapoznik[1], Dov Zippel[1], Roni Shapira[1], Michal J. Besser[1,2], Jacob Schachter[1], Gal Markel[1,2]
[1]*Sheba Medical Center, Tel-Hashomer, Israel*
[2]*Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel*

P-93 THE ROLE OF CEACAM1 IN METASTATIC MELANOMA AND THE DEVELOPMENT OF CEACAM1-TARGETED THERAPY

Rona Ortenberg[1,2], Sivan Sapoznik[1], Michal J. Besser[1,2], Liat Hershkoviz[1], Jacob Schachter[1], Gal Markel[1,2]
[1]*Sheba Medical Center, Tel-Hashomer, Israel*
[2] *Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel*

Board
No.

P-94 NRN1: A NEW MELANOMA THERAPEUTIC TARGET?
Rona Ortenberg[1,2], Gilli Galore-Haskel[1,2], Raz Mutai[2],
Jacob Schachter[1], Gal Markel[1,2]
[1]*Sheba Medical Center, Tel-Hashomer, Israel*
[2] *Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel*

P-95 CROSS TALK BETWEEN IL-1b and VEGF IS ESSENTIAL FOR TUMOR-MEDIATED ANGIOGENESIS
Elena Voronov[1], Yaron Carmi[1], Shahar Dotan[1], Malka R. White[1],
Monica Huszar[2], Peleg Rider[1], Irena Kaplanov[1],
Charles A. Dinarello[3], Ron N. Apte[1]
[1]*Ben-Gurion University of the Negev, Beer-Sheva, Israel,*
[2]*Kaplan Medical Center, Rehovot, Israel,* [3]*University of Colorado, Denver, USA*

P-96 THE EFFECTS OF IL-1 ON COLORECTAL CANCER DEVELOPMENT
Elena Voronov[1], Marina Bersudsky[1], Dmitry Fishman[1],
Malka R. White[1], Nadya Ziv-Sokolovsky[2], Charles A. Dinarello[3],
Ron N. Apte[1]
[1]*Ben-Gurion University of the Negev, Beer-Sheva, Israel*
[2]*Kaplan Medical Center, Rehovot, Israel*
[3]*University of Colorado Denver, Colorado, USA*

P-97 PIM-2-MEDIATED ACTIVATION OF THE DNA DAMAGE RESPONSE LEADS TO INCREASED VIABILITY FOLLOWING UV-RADIATION
Shahar Zirkin, Jeremy Don
Bar-Ilan University, Ramat-Gan, Israel

P-98 HUMAN Vav1 EXPRESSION IN HEMATOPOIETIC AND CANCER CELL LINES IS REGULATED BY c-Myb AND BY CpG METHYLATION
Lena Ilan, Shulamit Katzav
The Hebrew University of Jerusalem, Jerusalem, Israel

Board
No.

P-99 THE ROLE OF hnRNP A2/B1 IN BREAST CANCER DEVELOPMENT AND TUMOR STAGE

Regina Golan-Gerstl[1], Ilana Lebenthal-Loinger[1], Ben Davidson[2], Reuven Reich[1], Rotem Karni[1]
[1]*Hadassah Medical School - The Hebrew University of Jerusalem, Jerusalem, Israel,* [2]*Norwegian Radium Hospital, Rikshospitalet Medical Center, Oslo, Norway*

P-100 ALTERED GATA-3 FUNCTION IS ASSOCIATED WITH BREAST CANCER DEVELOPMENT AND PHENOTYPE

Helit Cohen, Rotem Ben-Hamo, Sol Efroni
Bar-Ilan University, Ramat-Gan, Israel

P-101 Vav1: THE ONCOGENIC SWITCH

Shulamit Sebban, Marganit Farago, Dan Gashai, Lea Tzadik, Shulamit Katzav
Hadassah Medical School - The Hebrew University of Jerusalem, Jerusalem, Israel

P-102 TNF-ALPHA JOINS FORCES WITH ESTROGEN AND EGF IN BREAST CANCER MICROENVIRONMENT, LEADING TO METASTASIS FORMATION BY POTENTIATING ADHESIVE AND MIGRATORY PROPERTIES

Polina Weitzenfeld[1], Eline Von Konigslow[1], David Naor[2], Eva Turley[3], Adit Ben-Baruch[1]
[1]*Tel-Aviv University, Tel-Aviv, Israel*
[2] *Hadassah Medical School - The Hebrew University of Jerusalem, Jerusalem, Israel*
[3]*University of Western Ontario and London Health Sciences Center, London, Canada*

Board
No.

P-103 DIFFERENTIAL EXPRESSION AND FUNCTIONS OF miRNAS IN GLIOMA STEM CELLS (GSCS) AND HUMAN NEURAL STEM CELLS (NSCS)

Ariel Bier[1], Michal Yalon[2,3], Elad Jacoby[2,3], Jasmine Jacob-Hirsch[2,3], Simona Cazacu[4], Susan Finniss[4], Cunli Xian[4], Hae-Kyung Lee[4], Tom Mikkelsen[4], Amos Toren[2,3], Chaya Brodie[1,4]
[1]*Bar-Ilan University, Ramat-Gan, Israel,* [2]*Sheba Medical Center, Tel-Hashomer, Israel,* [3]*Tel-Aviv University, Tel-Aviv, Israel*
[4]*Henry Ford Hospital, Detroit, MI, USA*

P-104 INTRACELLULAR GLYCOSAMINOGLYCANS AND CHEMOKINE DOMAINS REGULATE THE SECRETION OF THE PRO-MALIGNANCY CHEMOKINE CCL2 BY BREAST TUMOR CELLS

Yaeli Lebel-Haziv, Gali Soria, Tsipi Meshel, Marcelo Ehrlich, Adva Yeheskel, Elad Mamon, Adit Ben-Baruch
Tel-Aviv University, Tel-Aviv, Israel

P-105 PREDICTION OF RESPONSE TO ADOPTIVE IMMUNOTHERAPY IN ADVANCED MELANOMA PATIENTS

Daphna Levy, Orit Itzhaki, Adva Kobi, Dragoslav Dzikich, Yaara Ohyiun, Noa Shoshani, Ronnie Shapira, Jacob Schachter, Michal J. Besser
Sheba Medical Center, Tel-Hashomer, Israel

P-106 NICOTINAMIDE INHIBITS "VASCULOGENIC MIMICRY", AN ALTERNATIVE VASCULARIZATION PATHWAY OBSERVED IN HIGHLY AGGRESSIVE MELANOMA

Orit Itzhaki[1], Eyal Greenberg[1,2], Adva Kubi[1], Avraham Treves[1], Ronnie Shapira[1], Bruria Shalmon[1], Jacob Schachter[1], Michal J. Besser[1,2], Gal Markel[1,2]
[1]*Sheba Medical Center, Tel-Hashomer, Israel*
[2]*Tel-Aviv University, Tel-Aviv, Israel*

P-107 ONCOGENE-INDUCED SENESCENCE DEPENDS ON LOW CELLULAR NUCLEOTIDE POOL

Assaf C. Bester, Dan Sarni, Batsheva Kerem
The Hebrew University of Jerusalem, Jerusalem, Israel

Board
No.

P-108 ESCIN ALONE AND IN COMBINATION WITH CHEMOTHERAPY DECREASES PANCREATIC CANCER CELL SURVIVAL
Adam Rimmon, Akiva Vexler, Liron Berkovich, Gideon Earon, Ilan Ron, Shahar Lev-Ari
Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

P-109 THE ROLE OF hnRNP A1/A2 PROTEINS IN HEPATOCELLULAR CARCINOMA DEVELOPMENT AND PROGRESSION
Asaf Shilo[1], Ilan Stein[1], Eli Pikarsky[1], Lars Zender[2], Rotem Karni[1]
[1] *Hadassah Medical School - The Hebrew University of Jerusalem, Jerusalem, Israel*
[2]*Hannover Medical School, Hannover, Germany*

P-110 THE MOLECULAR MECHANISM OF MET-INDUCED PATH FINDING- AMOEBOID CELL MOTILITY TOWARDS METASTASIS
Tammy Diamant-Levi, Adi Laser, Dganit Shkedy, Gideon Stein, Judith Horev, Ilan Tsarfaty
Tel-Aviv University, Tel-Aviv, Israel

P-111 SELECTIVE IMPACT OF THE HISTONE DEACETYLASE INHIBITORS ON TUMOR AND NORMAL CELLS
Nataly Tarasenko[1], Gabriela Rozic[1], Pnina Boer[1], Aida Inbal[1], Abraham Nudelman[2], Ada Rephaeli[1]
[1]*Sackler Faculty of Medicine, Tel-Aviv University, Petach-Tikva, Israel,* [2]*Bar-Ilan University, Ramat- Gan, Israel*

P-112 DIFFERENTIAL REGULATION OF TRANSFORMING GROWTH FACTOR β (TGF-β) SIGNALING UPON MITOTIC ARREST OF OVARIAN CANCER CELLS
Tal Hirschhorn, Lior Barzily, Nechama I. Smorodinsky, Marcelo Ehrlich
Tel-Aviv University, Tel-Aviv, Israel

Board
No.

P-113 IDENTIFICATION OF MELANOMA-REACTIVE T CELLS BASED ON ACQUISITION OF TUMOR ANTIGEN
Galit Eisenberg[1], Arthur Machlenkin[1], Shoshana Frankenburg[1], Ronny Uzana[1], Soldano Ferrone[2], Eitan Yefenof[3], Tamar Peretz[1], Michal Lotem[1]
[1]*Hadassah Medical Organization, Jerusalem, Israel*
[2]*University of Pittsburgh Cancer Institute, Pittsburgh, USA*
[3]*The Hebrew University of Jerusalem, Jerusalem, Israel*

P-114 MOLECULAR MECHANISMS OF CHEMOTHERAPY INDUCED SENESCENCE IN HUMAN LUNG CANCER
Reut Yosef-Hemo, Valery Krizhanovsky
Weizmann Institute of Science, Rehovot, Israel

P-115 SYSTEM BIOLOGY APPROACHES FOR PREDICTING AND CONTROLLING THE ANTI-TUMOR REACTIVITY OF TUMOR INFILTRATING LYMPHOCYTES
Moran Hod[1], Kfir Oved[1], Michal J. Besser[2], Yoram Reiter[1]
[1]*Technion-Israel Institute of Technology, Haifa, Israel*
[2]*Sheba Medical Center, Tel-Hashomar, Israel*

P-116 BREAST CANCER INFLAMMATORY CYTOKINES MAKE NON-TRANSFORMED CELLS POTENTIAL CANDIDATES FOR RE-SEEDING AT THE PRIMARY TUMOR SITE
Tal Leibovich-Rivkin, Tsipi Meshel, Adit Ben-Baruch
Tel-Aviv University, Tel-Aviv, Israel

P-117 REGULATION OF PRO-MALIGNANCY TRAITS IN MESENCHYMAL STEM CELLS RECRUITED TO BREAST TUMORS
Shalom Lerrer, Christina Katanov, Adit Ben-Baruch
Tel-Aviv University, Tel-Aviv, Israel

P-118 STRUCTURE-FUNCTION STUDY OF THE SPLICING FACTOR SRSF1 IN CELLULAR TRANSFORMATION
Ariel Shimoni-Sebag[1], Lars Zender[2], Rotem Karni[1]
[1]*The Hebrew University of Jerusalem, Jerusalem, Israel*
[2]*Hepatology and Endocrinology Hannover Medical High School, Hannover, Germany*

Board
No.

P-119 MEIG1 KO MICE ARE PREDISPOSED TO TUMOR DEVELOPMENT
Revital Yaverboim, Tali Eldar, Jeremy Don
Bar-Ilan University, Ramat- Gan, Israel

P-120 ONCOPATHWAY ADDICTION AS MASTER REGULATOR OF CANCER PROGRESSION/h1
Shay Shilo, Sol Efroni
Bar-Ilan University, Ramat-Gan, Israel

P-121 INCREASED INFLAMMATION AND ANGIOGENESIS IN PPM1A KO MICE
Zeev Dvashi[1], Hadas Jacobi[1], Maytal Shohat[1], Daniella Ben-Meir[1], Ruth Ashery-Padan[2], Shiran Ferber[4], Mordechai Rosner[3], Ronit Satchi-Fainaro[2], Arieh S. Solomon[3], Sara Lavi[1]
[1]*Faculty of Life Sciences, Tel-Aviv University, Tel-Aviv, Israel*
[2]*Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel*
[3]*Tel-Aviv University, Tel-Aviv, Israel*

P-122 Mimp/Mtch2 A MITOCHONDRIAL CARRIER HOMOLOG THAT PLAYS AN IMPORTANT ROLE IN TUMORIGENICITY AND OBESITY
Yamit Bar-Lev, Orly Cohen-Neeman, Raya Leibowitz-Amit, Gideon Stein, Gil Yerushalmi, Sharon Moshitch-Moshkovitz, Ilan Tsarfaty
Tel-Aviv University, Tel-Aviv, Israel

P-123 A POTENTIAL FUNCTIONAL INTERACTION BETWEEN THE HUMAN GLIOMA TUMOR SUPPRESSOR CANDIDATE REGION 2 (GLTSCR2) GENE PRODUCT AND TP53
Avi-ad Buskila, Ronit Sarid
Bar-Ilan University, Ramat-Gan, Israel

P-124 THE ROLE OF EFFUSION-DERIVED EXOSOMES FROM OVARIAN CARCINOMA PATIENTS IN MALIGNANT PROGRESSION
Olga Vaksman[1], Ben Davidson[2], Claes G. Trope'[2], Reuven Reich[1]
[1]*The Hebrew University of Jerusalem, Jerusalem, Israel*
[2]*Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway*

Board
No.

P-125 CYP2D6 GENOTYPING FOR TAMOXIFEN ADMINISTRATION
Flavio Lejbkowicz, Ilana Cohen, Gad Rennert
CHS National Cancer Control Center and Carmel Medical Center and Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

P-126 DETECTION OF UGT1A1*28 GENOTYPE IN CRC PATIENTS
Flavio Lejbkowicz, Ilana Cohen, Katerina Shulman, Gad Rennert
CHS National Cancer Control Center and Carmel Medical Center and Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

P-127 TARGETING EGFR POSITIVE CANCER CELLS WITH CETUXIMAB-ZZ-PE38: RESULTS OF *IN VITRO* AND *IN VIVO* STUDIES
Rahamim Ben-Yosef[1], Itay Barnea[1], Victoria Karaush[1], Itai Benhar[2], Akiva Vexler[1]
[1]*Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel*
[2]*Tel-Aviv University, Tel-Aviv, Israel*

P-128 A NETWORK BIOLOGY APPROACH TO DECIPHER MELANOMA PATHWAYS
Yossi Kuttner, **Esti Yeger-Lotem**
Ben-Gurion University of the Negev, Beer-Sheva, Israel

P-129 LIPID RAFTS COUPLE STORE-OPERATED Ca^{2+}-ENTRY TO CONSTITUTIVE ACTIVATION OF PKB/Akt IN A Ca^{2+}/calmodulin-, Src- AND PP2A-MEDIATED PATHWAY, AND PROMOTE MELANOMA TUMOR GROWTH
Shlomit Fedida-Metula, Ben Feldman, Ulianna Levin-Gromiko, Valeria Koshelev, Elena Voronov, **Daniel Fishman**
Ben-Gurion University of the Negev, Beer-Sheva, Israel

P-130 SIGNIFICANT ANTICANCER EFFECT OF NOVEL 9-ANILINOACRIDINES ON MOST EPITHELIAL ORIGIN CANCERS: MECHANISM OF ACTION
Stella Aronov, Tzipi Beker, Maria Bogdansky, Amilia Meir, Katia Karakov, Garry Gellerman
Ariel University Center of Samaria, Ariel, Israel

Board
No.

P-131 AUTOLOGOUS RENAL CELL CARCINOMA VACCINES – INITIAL REPORT

Hovav Nechushtan, Merav Darash-Yahana, Tamar Hamburger, Inna Ben-David, Anna Kuznetz, Yael Gelfand, Aviad Zick, Ofer Gofrit, Tamar Peretz, Michal Lotem
Hadassah Medical Center - The Hebrew University of Jerusalem, Jerusalem, Israel

P-132 PKCη IS A NOVEL PROGNOSTIC MARKER IN NON-SMALL CELL LUNG CANCER

Ella Krasnitsky[1], Yael Baumfeld[2], Janna Freedman[2], Netta Sion-Vardi[2], Samuel Ariad[2], Victor Novack[2], Etta Livneh[1]
[1]*Ben-Gurion University of the Negev, Beer-Sheva, Israel*
[2]*Soroka University Medical Center, Beer-Sheva, Israel*

P-133 PKCeta IS A NEGATIVE REGULATOR OF AKT INHIBITING THE IGF-I INDUCED PROLIFERATION

Noa Rotem-Dai, Galit Shahaf, Gabriela Koifman, Hadas Raveh-Amit, Sigal Adriana Frost, Etta Livneh
Ben-Gurion University of the Negev, Beer-Sheva, Israel

P-134 DIMERIZATION OF NKp46 RECEPTOR IS ESSENTIAL FOR NKp46-MEDIATED LYSIS: CHARACTERIZATION OF THE DIMERIZATION SITE BY EPITOPE MAPPING

Rami Yossef, Michal Mendelson, Appel Michael Y., Alon Zilka, Uzi Hadad, Fabian Afergan, Benyamin Rosental, Stanislav Engel, Alex Braiman, Angel Porgador
Ben-Gurion University of the Negev, Beer-Sheva, Israel